Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05615142

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Phase I Study of Low Dose Radiotherapy and Concurrent SBRT in Combination With PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer (NSCLC) .

Sponsor: Sichuan University

Conditions Low Dose Radiotherapy NSCLC PD-1 Inhibitor Stereotactic Body Radiotherapy

Interventions Low Dose Radiotherapy PD-1 Inhibitors stereotactic body radiation therapy

Updated 4 times since 2022 Last updated: Apr 15, 2024 Started: Dec 15, 2021 Primary completion: Jun 30, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Low Dose Radiotherapy and NSCLC and is currently actively recruiting participants. Sichuan University leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Dec 2022 — May 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan University

Data source: Sichuan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China